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Background:		
Survival	outcomes	for	pancrea.c	cancer	remain	poor.	Surgical	resec.on	is	the	only	poten.ally	cura.ve	treatment	but	approximately	10%	present	with	resectable	disease	with	5year	survival	for	resected	cases	
between	only	7%	and	25%.	Adjuvant	therapy	aYer	surgery	is	required	to	prolong	survival	but	up	to	50%	of	pa.ents	fail	to	receive	adjuvant	therapy.	Neoadjuvant	therapy	has	emerged	as	an	alterna.ve	
treatment	strategy	but	carries	the	risk	of	loosing	the	window	of	resectability.	Risks	of	failure	therefore	exist	throughout	both	treatment	pathways.	Recent	decision-analysis	have	suggested	that	the	selec.on	of	
op.mal	treatment	pathways	depends	on	individual	pa.ent	and	tumour	factors.	This	paper	presents	a	Bayesian	Belief	Network	(BBN)	model	that	evaluates	the	risk	of	failure	and	consequence	factors	across	
surgery-first	and	neoadjuvant	pathways.	BBN	is	capable	of	providing	personalized	predic.ons	of	good	prognosis	(3year	survival)	post	resec.on	of	pancrea.c	ductal	adenocarcinoma.	This	can	support	clinical	
decision	ac.on	and	pa.ent	counseling	by	iden.fying	superior	pathway	selec.on	at	individualized	level,	and	jus.fy	resource	alloca.on	by	iden.fying	pa.ents	at	higher	risk	of	failure	who	require	addi.onal	
ac.ons	to	reduce	risk.		
	
Methods	1:		
BBN,	also	referred	to	as	acyclic	directed	graphs,	is	a	graphical	model	based	on	probability	theory	that	models	rela.onships	between	variables.	BBN	consist	of	variables,	know	as	nodes,	with	arcs	depic.ng	
informa.onal	or	causal	rela.onships	from	parent	to	child	nodes.	Each	node	has	a	defined	and	exclusive	set	of	states	and	the	dependencies	between	nodes	are	quan.fied	through	a	set	of	condi.onal	probability	
tables	(CPTs)	whereby	the	condi.onal	probability	of	a	child	node	is	defined	by	the	state	of	each	of	its	parent	nodes.	Nodes	that	do	not	have	parent	nodes	are	reduced	to	the	uncondi.onal	probability	(UP)	
structure.	Where	the	UPs	of	a	basic	input	parameter	is	not	known	a	priori,	equal	weight	are	applied	to	states	through	the	principle	of	insufficient	reasoning.			
Through	Baye’s	theorem,	BBN	can	explicitly	represent	the	condi.onal	probability	dependencies	between	variables,	which	has	been	proven	to	be	an	effec.ve	way	of	handling	uncertainty.	In	a	BBN,	the	updated	
probability	for	n	number	of	mutually	exclusive	parameters	Xi,	where	(i=	1,2,3…n),	and	given	observed	data,	Y,	can	be	computed	as:	p(Xi|Y)=	pYXix	p(Xi)∑jpYXjp(Xj	where	the	posterior	probability	of	X	given	the	
condi.on	that	Y	occurs	is	represented	by	p(X|Y),	the	posterior	probability	of	Y	given	the	condi.on	that	X	occurs	is	represented	by	p(Y|X),	the	prior	occurrence	probability	of	X	is	denoted	by	p(X)	and	the	
marginal	occurrence	of	Y	is	denoted	as	p(Y)	.	In	this	sense	this	is	oYen	viewed	as	the	likelihood	distribu.on.		
		
This	holds	several	advantages	when	modeling	treatment	pathways	for	poten.ally	resectable	PDAC.	Through	Bayes	theorem	the	prior	distribu.on	and	observed	data	are	combined	to	update	knowledge	in	the	
form	of	the	posterior	distribu.on.	Therefore	BBNs	allow	the	modeling	of	rela.onships	between	variables	at	various	stages	of	the	healthcare	process,	with	predic.ons	of	outcomes	evolving	throughout	the	
process	by	u.lizing	all	available	pa.ent	data	at	that	.me.	This	means	that	the	model	could	not	only	make	predic.ons	of	outcome	pre-opera.vely	but	also	perform	prognos.c	upda.ng	at	the	post-opera.ve	
stage	of	the	pa.ent	journey.	Where	pa.ent	informa.on	is	limited	probabilis.c	inference	can	s.ll	make	predic.ons	based	on	global	averages	of	the	pa.ent	popula.on.	As	more	informa.on	becomes	available	
the	predic.ons	become	more	pa.ent	specific.	Furthermore,	BBN	have	the	flexibility	to	perform	bogom-up	inference	(inferring	the	state	of	the	parent	node	from	the	observed	state	of	the	child	node)	and	top-
down	inference	(inferring	the	state	of	the	child	node	given	the	observed	state	of	the	parent	node).	This	is	also	known	as	diagnos.c	and	decision	analysis	respec.vely	and	is	called	marginaliza.on	which	is	
employed	to	compute	the	reliability	of	networks	based	on	sta.s.cal	data.	For	the	pancrea.c	cancer	model	this	process	will	also	allow	the	tes.ng	of	the	model	to	perform	scenario,	or	“what	if”	tes.ng	to	
an.cipate	cause	and	impact	of	failure	events	such	as	developing	side	effects	from	therapy	or	complica.ons	from	surgery.		
Methods	2:		
A	weighted	prognos.c	BBN	was	created	using	AgenaRisk	soYware.	The	BBN	was	based	on	data	from	
survival	analysis	studies	gathered	from	a	comprehensive	search	of	PubMed	database	(n=48691)	that	
was	synthesized	based	on	a	two-stage	weigh.ng	process.	The	model	was	validated	against	a	
prospec.vely	maintained	pa.ent	database	from	a	ter.ary	referral	centre	(n=365).	Variables	know	at	
the	pre-opera.ve	stage	of	the	pa.ent	journey	were	included	in	the	pre-opera.ve	BBN	and	post-
opera.ve	factors	were	added	to	the	model	to	perform	prognos.c	upda.ng.	Individual	pa.ent	data	was	
entered	into	the	BN	and	the	personalized	pre	and	post-opera.ve	predic.ons	of	poor	prognosis	were	
recorded	and	assessed	against	that	individual’s	actual	survival	.me	therefore	deeming	predic.ons	to	be	
true	or	false.		
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Results:	
Pre-opera.ve	Results	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Post-opera.ve	Results	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
The	BBN	demonstrated	a	high	level	of	predic.ve	performance.	Benefits	over	exis.ng	models	include:	pre-opera.ve	applica.on,	greater	generalizability,	and	ability	to	encompass	both	upfront	surgery	and	
neoadjuvant	treatment	op.ons.	This	marks	an	important	step	towards	achieving	the	delivery	of	precision	medicine,	as	the	next	step	will	be	to	incorporated	genomic	data	into	the	model	hence	combining	
gene.c,	pathology	and	clinical	data,	crea.ng	a	vehicle	to	deliver	personalized	precision	medicine.		
Methods	3:	Sensi.vity	Analysis		
Pearl’s	inwards	analysis	and	broadcas.ng	analysis	were	used	to	perform	sensi.vity	analysis.	
This	showed	that	for	the	pre-opera.ve	BBNs	tumour	factors	had	the	greatest	impact	on	
outcomes,	followed	by	pa.ent	factors.	When	post-opera.ve	data	was	incorporated	into	the	
BBN	post-opera.ve	factors	and	surgical	pathology	had	greatest	impact	on	output	followed	by	
tumour	factors	and	pa.ent	factors.			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
